Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Autoimmune diseases more common in women who stop ovulating before 40

Autoimmune diseases more common in women who stop ovulating before 40

Microbial biomarkers identified in lupus and IBD offer pathways for targeted therapies

Microbial biomarkers identified in lupus and IBD offer pathways for targeted therapies

Genetic discovery reveals key to inflammatory diseases

Genetic discovery reveals key to inflammatory diseases

Risk factors for serious inflammatory conditions in IBD patients identified

Risk factors for serious inflammatory conditions in IBD patients identified

Study sheds light on early life risk factors for ankylosing spondylitis

Study sheds light on early life risk factors for ankylosing spondylitis

IL-17: The molecule that could revolutionize autoimmune and cancer treatments

IL-17: The molecule that could revolutionize autoimmune and cancer treatments

COVID-19 heightens risk of autoimmune disorders

COVID-19 heightens risk of autoimmune disorders

Is there an association between psoriasis onset and risk of autoimmune disease?

Is there an association between psoriasis onset and risk of autoimmune disease?

How do viral infections cause autoimmune diseases?

How do viral infections cause autoimmune diseases?

Investigating the impact of COVID-19 vaccinations in immunocompromised adult patients

Investigating the impact of COVID-19 vaccinations in immunocompromised adult patients

Self-directed autoantibodies against certain chemokines may protect against long-COVID

Self-directed autoantibodies against certain chemokines may protect against long-COVID

Study shows how arthritis affects people's working lives

Study shows how arthritis affects people's working lives

Combination treatment does not slow radiographic spinal progression in radiographic axSpA patients

Combination treatment does not slow radiographic spinal progression in radiographic axSpA patients

Study estimates the quality of care for patients with long-term health conditions

Study estimates the quality of care for patients with long-term health conditions

New data analysis approach could help uncover the genetic basis of many diseases

New data analysis approach could help uncover the genetic basis of many diseases

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Exploring the effectiveness of various treatments in people with axial spondyloarthritis

Exploring the effectiveness of various treatments in people with axial spondyloarthritis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.